BACKGROUND: HIV antiretroviral therapy (ART) is being rapidly scaled up in sub-Saharan Africa, including recently patients with CD4 T-cell counts above 350 cells/μl. However, concerns persist about adherence and virologic suppression among these asymptomatic, high CD4 cell count individuals. OBJECTIVE: To determine the virologic efficacy and safety of ART among asymptomatic HIV-positive Ugandan adults with high CD4 cell counts above 350 cells/μl via a streamlined model of care. DESIGN: Prospective nonrandomized clinical study (EARLI Study: clinicaltrials.gov NCT#01479634). SETTING: Prototypic rural Ugandan HIV clinic. PATIENTS/PARTICIPANTS: Asymptomatic, ART-naive adults (aged >18 years, N = 197) with CD4 at least 350 cells/μl, without pregnancy or WHO stage 3/4 illness. INTERVENTIONS: ART included tenofovir/emtricitabine/efavirenz, with ritonavir/lopinavir substitution for efavirenz available. Streamlined ART model included nurse-driven visits with physician back-up, basic safety laboratory monitoring with HIV viral load, clinician telephone contact, and defaulter tracking. No incentives were provided. OUTCOMES: Undetectable viral load (≤400 copies/ml) at 24 and 48 weeks [intention to treat (ITT); missing = detectable), self-reported ART adherence, retention in care, and laboratory/clinical ART toxicities. RESULTS: Of the 197 patients with CD4 above 350 cells/μl, median CD4 cell count was 569 cells/μl (interquartile range 451-716). Undetectable viral load was achieved in 189 of 197 (95.9%, ITT) and 189 of 195 (96.9%, ITT) of participants at weeks 24 and 48, respectively. Self-reported adherence was 98% and 192 of 197 (97%) of the patients were retained at week 48. Laboratory adverse events and hospitalizations were rare. CONCLUSIONS: We demonstrate high virologic suppression, retention, and safety among asymptomatic individuals with CD4 above 350 cells/μl in a prototypic Ugandan clinic. Our results challenge current concerns that individuals with high CD4 cell count lack motivation for ART, and may not achieve sustained virologic suppression.
BACKGROUND: HIV antiretroviral therapy (ART) is being rapidly scaled up in sub-Saharan Africa, including recently patients with CD4 T-cell counts above 350 cells/μl. However, concerns persist about adherence and virologic suppression among these asymptomatic, high CD4 cell count individuals. OBJECTIVE: To determine the virologic efficacy and safety of ART among asymptomatic HIV-positive Ugandan adults with high CD4 cell counts above 350 cells/μl via a streamlined model of care. DESIGN: Prospective nonrandomized clinical study (EARLI Study: clinicaltrials.gov NCT#01479634). SETTING: Prototypic rural Ugandan HIV clinic. PATIENTS/PARTICIPANTS: Asymptomatic, ART-naive adults (aged >18 years, N = 197) with CD4 at least 350 cells/μl, without pregnancy or WHO stage 3/4 illness. INTERVENTIONS:ART included tenofovir/emtricitabine/efavirenz, with ritonavir/lopinavir substitution for efavirenz available. Streamlined ART model included nurse-driven visits with physician back-up, basic safety laboratory monitoring with HIV viral load, clinician telephone contact, and defaulter tracking. No incentives were provided. OUTCOMES: Undetectable viral load (≤400 copies/ml) at 24 and 48 weeks [intention to treat (ITT); missing = detectable), self-reported ART adherence, retention in care, and laboratory/clinical ARTtoxicities. RESULTS: Of the 197 patients with CD4 above 350 cells/μl, median CD4 cell count was 569 cells/μl (interquartile range 451-716). Undetectable viral load was achieved in 189 of 197 (95.9%, ITT) and 189 of 195 (96.9%, ITT) of participants at weeks 24 and 48, respectively. Self-reported adherence was 98% and 192 of 197 (97%) of the patients were retained at week 48. Laboratory adverse events and hospitalizations were rare. CONCLUSIONS: We demonstrate high virologic suppression, retention, and safety among asymptomatic individuals with CD4 above 350 cells/μl in a prototypic Ugandan clinic. Our results challenge current concerns that individuals with high CD4 cell count lack motivation for ART, and may not achieve sustained virologic suppression.
Authors: Ingrid T Katz; Thandekile Essien; Edmore T Marinda; Glenda E Gray; David R Bangsberg; Neil A Martinson; Guy De Bruyn Journal: AIDS Date: 2011-11-13 Impact factor: 4.177
Authors: Michael L Rich; Ann C Miller; Peter Niyigena; Molly F Franke; Jean Bosco Niyonzima; Adrienne Socci; Peter C Drobac; Massudi Hakizamungu; Alishya Mayfield; Robert Ruhayisha; Henry Epino; Sara Stulac; Corrado Cancedda; Adolph Karamaga; Saleh Niyonzima; Chase Yarbrough; Julia Fleming; Cheryl Amoroso; Joia Mukherjee; Megan Murray; Paul Farmer; Agnes Binagwaho Journal: J Acquir Immune Defic Syndr Date: 2012-03-01 Impact factor: 3.731
Authors: Alice Nakiwogga-Muwanga; Elly Katabira; Joseph Sempa; Andrew Kambugu; Esther Nakibuuka-Lubwama; Mohammed Lamorde; Joseph Mawejje; Robert Colebunders Journal: J Int Assoc Provid AIDS Care Date: 2013-06-06
Authors: M W Nanteza; H Mayanja-Kizza; E Charlebois; P Srikantiah; R Lin; E Mupere; P Mugyenyi; W H Boom; R D Mugerwa; D V Havlir; C C Whalen Journal: J Infect Dis Date: 2011-09-15 Impact factor: 5.226
Authors: Susan A Adakun; Mark J Siedner; Conrad Muzoora; Jessica E Haberer; Alexander C Tsai; Peter W Hunt; Jeff N Martin; David R Bangsberg Journal: J Acquir Immune Defic Syndr Date: 2013-03-01 Impact factor: 3.731
Authors: Gabriel Chamie; Dalsone Kwarisiima; Tamara D Clark; Jane Kabami; Vivek Jain; Elvin Geng; Maya L Petersen; Harsha Thirumurthy; Moses R Kamya; Diane V Havlir; Edwin D Charlebois Journal: PLoS One Date: 2012-08-20 Impact factor: 3.240
Authors: Norma C Ware; Monique A Wyatt; Elvin H Geng; Sylvia F Kaaya; Oche O Agbaji; Winnie R Muyindike; Guerino Chalamilla; Patricia A Agaba Journal: PLoS Med Date: 2013-01-08 Impact factor: 11.069
Authors: Lillian B Brown; Diane V Havlir; James Ayieko; Florence Mwangwa; Asiphas Owaraganise; Dalsone Kwarisiima; Vivek Jain; Theodore Ruel; Tamara Clark; Gabriel Chamie; Elizabeth A Bukusi; Craig R Cohen; Moses R Kamya; Maya L Petersen; Edwin D Charlebois Journal: AIDS Date: 2016-11-28 Impact factor: 4.177
Authors: Lillian B Brown; James Ayieko; Florence Mwangwa; Asiphas Owaraganise; Dalsone Kwarisiima; Vivek Jain; Theodore Ruel; Tamara Clark; Douglas Black; Gabriel Chamie; Elizabeth A Bukusi; Craig R Cohen; Moses R Kamya; Maya L Petersen; Edwin D Charlebois; Diane V Havlir Journal: J Acquir Immune Defic Syndr Date: 2017-09-01 Impact factor: 3.731
Authors: Starley B Shade; Thomas Osmand; Dalsone Kwarisiima; Lillian B Brown; Alex Luo; Betty Mwebaza; Aine Ronald Mwesigye; Enos Kwizera; Haawa Imukeka; Florence Mwanga; James Ayieko; Asiphas Owaraganise; Elizabeth A Bukusi; Craig R Cohen; Edwin D Charlebois; Douglas Black; Tamara D Clark; Maya L Petersen; Moses R Kamya; Diane V Havlir; Vivek Jain Journal: AIDS Date: 2021-05-01 Impact factor: 4.632
Authors: Francesca Celletti; Jennifer Cohn; Catherine Connor; Stephen Lee; Anja Giphart; Julio Montaner Journal: J Int AIDS Soc Date: 2016-12-16 Impact factor: 5.396
Authors: Vivek Jain; Wei Chang; Dathan M Byonanebye; Asiphas Owaraganise; Ellon Twinomuhwezi; Gideon Amanyire; Douglas Black; Elliot Marseille; Moses R Kamya; Diane V Havlir; James G Kahn Journal: PLoS One Date: 2015-12-03 Impact factor: 3.240
Authors: Stephen Okoboi; Erin Ding; Steven Persuad; Jonathan Wangisi; Josephine Birungi; Susan Shurgold; Darius Kato; Maureen Nyonyintono; Aggrey Egessa; Celestin Bakanda; Paula Munderi; Pontiano Kaleebu; David M Moore Journal: AIDS Res Ther Date: 2015-11-12 Impact factor: 2.250
Authors: Naomi N Bock; Ruth C Emerson; Jason B Reed; Rejoice Nkambule; Deborah J Donnell; George T Bicego; Velephi Okello; Neena M Philip; Peter D Ehrenkranz; Yen T Duong; Janet S Moore; Jessica E Justman Journal: J Acquir Immune Defic Syndr Date: 2016-03-01 Impact factor: 3.731